Negative: Ames assay and in vivo rat bone marrow micronucleus assay
“Defibrotide was not mutagenic in the in vitro bacterial reverse mutation assay (Ames assay) nor was it clastogenic in an in vivo bone marrow micronucleus assay in rats.”
✓ VerifiedFDA pharmacology/toxicology review, p. 5Source ↗
Carcinogenicity
Not conducted by the intravenous route; oral studies inadequate to assess carcinogenic potential
“No carcinogenicity studies have been conducted with defibrotide administered by the intravenous route and the oral studies were inadequate to conduct an assessment of the potential for carcinogenicity.”
✓ VerifiedFDA pharmacology/toxicology review, p. 5Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Rabbit embryo-fetal toxicity: fewer implantations and viable fetuses at doses about equal to the clinical dose (mg/m2)
“Exposure to defibrotide was associated with embryo-fetal toxicity (decreased number of implantations and viable fetuses compared to controls) in pregnant rabbits at doses approximately equivalent to the recommended clinical dose on a mg/m2 basis.”
✓ VerifiedFDA pharmacology/toxicology review, p. 4Source ↗
Safety pharmacology
No hERG inhibition up to 500 µg/mL; ECG incorporated into 13-week dog infusion study
“Defibrotide did not reduce hERG tail current at concentrations up to 500 μg/ml. ECG examinations were performed as part of a 13 week intravenous infusion toxicity study in dogs.”
Chromosomal aberration in Chinese hamster ovary cells: negative
“Defibrotide sodium was not clastogenic in an in vitro chromosomal aberrations assay in Chinese hamster ovary cells or an in vivo micronucleus assay conducted in bone marrow from rats administered defibrotide sodium by intravenous infusion.”
“Defibrotide sodium was not clastogenic in an in vitro chromosomal aberrations assay in Chinese hamster ovary cells or an in vivo micronucleus assay conducted in bone marrow from rats administered defibrotide sodium by intravenous infusion.”
No IV carcinogenicity studies; oral studies inadequate for assessment
“No carcinogenicity studies have been conducted with defibrotide administered by the intravenous route and the oral studies were inadequate to conduct an assessment of the potential for carcinogenicity.”
✓ VerifiedFDA pharmacology/toxicology review, p. 5Source ↗
Carcinogenicity timing
No IV carcinogenicity studies; oral mouse and rat studies inadequate; none required for approval
“No carcinogenicity studies have been conducted with defibrotide administered by the intravenous route and the oral studies were inadequate to conduct an assessment of the potential for carcinogenicity.”
✓ VerifiedFDA pharmacology/toxicology review, p. 5Source ↗
hERG / QT
Negative: no hERG tail current reduction up to 500 µg/mL
“Defibrotide did not reduce hERG tail current at concentrations up to 500 μg/ml.”